Patrys raises cash, shaves loss in FY12
Thursday, 23 August, 2012
Patrys (ASX:PAB) improved its financial position in FY12, narrowing its annual loss by 31.2% and raising $5.5 million through two placements.
In its annual report, Patrys said the capital raising initiatives should give it a cash runway until early 2014.
The company posted a net loss for the year of $5.1 million, from $7.4 million in 2011.
The main contributor to the lower loss was a 23.3% reduction in R&D costs, as the company shifted focus towards clinical and preclinical development of three antibody-based cancer treatment candidates.
These include PAT-SM6 - which is at the trial stage as a treatment of melanoma and also being assessed in multiple myeloma – and PAT-SC1, a gastric cancer treatment candidate which Patrys plans to pursue outlicensing arrangements for.
Patrys said that over the next 12 months it plans to commence a multi-dose Phase I/IIa clinical trial of PAT-SM6 in multiple myeloma, commence the hunt for an outlicensing partner for PAT-SC1, and prepare a third antibody treatment candidate for an eventual trial.
The company is in the process of concluding an up to $800,000 share purchase plan, which is scheduled to wrap up at the end of the month.
Patrys (ASX:PAB) shares grew 9.09% in Wednesday's trading, but were trading 4.17% lower at $0.023 as of around 3pm on Thursday.
COVID vaccine candidate protects against multiple variants
By targeting features shared by a range of coronaviruses, the vaccine is designed to offer...
Stevia leaf extract has potential as an anticancer treatment
When fermented with bacteria isolated from banana leaves, stevia extract kills off pancreatic...
Even non-antibiotics can disrupt the microbiome
Many non-antibiotics inhibit useful gut bacteria, giving rise to an imbalance in the microbiome,...
